Taiwan Small Molecule Innovator Api Cdmo Market Size & Outlook
Taiwan small molecule innovator api cdmo, 2018-2030 (US$M)
Related Markets
Taiwan small molecule innovator api cdmo highlights
- The Taiwan small molecule innovator api cdmo generated a revenue of USD 509.8 million in 2023 and is expected to reach USD 812.9 million by 2030.
- The Taiwan market is expected to grow at a CAGR of 6.9% from 2024 to 2030.
- In terms of segment, clinical was the largest revenue generating stage type in 2023.
- Commercial is the most lucrative stage type segment registering the fastest growth during the forecast period.
Small molecule innovator api cdmo data book summary
| Market revenue in 2023 | USD 509.8 million |
| Market revenue in 2030 | USD 812.9 million |
| Growth rate | 6.9% (CAGR from 2023 to 2030) |
| Largest segment | Clinical |
| Fastest growing segment | Commercial |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Preclinical, Commercial, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Thermo Fisher Scientific Inc, Siegfried Holding AG, Recipharm, CordenPharma, Samsung BioLogics, Labcorp Holdings Inc, Ajinomoto Co Inc, Piramal Pharma Solutions, Jubilant Biosys, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, Taiwan accounted for 1.7% of the global small molecule innovator api cdmo in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China small molecule innovator api cdmo is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 5,200.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Small Molecule Innovator API CDMO Scope
Small Molecule Innovator API CDMO Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Taiwan small molecule innovator api cdmo outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to small molecule innovator api cdmo will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 60.36% in 2023. Horizon Databook has segmented the Taiwan small molecule innovator api cdmo based on preclinical, commercial, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
- Taiwan Small Molecule Innovator API CDMO Stage Type Outlook (Revenue, USD Million, 2018-2030)
- Preclinical
- Commercial
- Clinical
- Phase I
- Phase II
- Phase III
- Taiwan Small Molecule Innovator API CDMO Customer Type Outlook (Revenue, USD Million, 2018-2030)
- Pharmaceutical
- Small
- Medium
- Large
- Biotechnology
- Small
- Medium
- Large
- Pharmaceutical
- Taiwan Small Molecule Innovator API CDMO Therapeutic Area Outlook (Revenue, USD Million, 2018-2030)
- Cardiovascular diseases
- Oncology
- Respiratory disorders
- Neurology
- Metabolic Disorders
- Infectious Diseases
- Others
Reasons to subscribe to Taiwan small molecule innovator api cdmo databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Taiwan small molecule innovator api cdmo databook
-
Our clientele includes a mix of small molecule innovator api cdmo companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Taiwan small molecule innovator api cdmo, including forecasts for subscribers. This country databook contains high-level insights into Taiwan small molecule innovator api cdmo from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Taiwan small molecule innovator api cdmo market report size, by stage type, 2018-2030 (US$M)
Taiwan Small Molecule Innovator API CDMO Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
